46 results found.

Breast Neoplasms, Ovarian Neoplasms, Colonic Neoplasms, Prostatic Clinical Trial

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers.

Breast Neoplasms, or Stomach Neoplasms Clinical Trial using Herceptin; afatinib; trastuzumab

Boehringer Ingelheim - Recruiting 18 years or older.
- Phase I Trial of Afatinib in Combination With 3 Weekly Trastuzumab in Patients With Tumours Overexpressing HER2. Once the MTD of Afatinib With 3 Weekly Trastuzumab Was Established the Safety of This Dose Will be Assessed Also in Combination With Weekly Trastuzumab..
Herceptin; afatinib; trastuzumab

Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasm Clinical Trial using 5-Fluoro-2-Deoxycytidine (FdCyd); Tetrahydrouridine (THU)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU).
5-Fluoro-2-Deoxycytidine (FdCyd); Tetrahydrouridine (THU)

Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasm Clinical Trial using Tetrahydrouridine (THU); [F-18]-5-FLUORO-2'-DEOXYCYTIDINE

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine.
Tetrahydrouridine (THU); [F-18]-5-FLUORO-2'-DEOXYCYTIDINE

Breast Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 74 years.
- A Multidisciplinary Study of Breast Cancer in Ghana: Pilot Phase.

Breast Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 30 years to 70 years.
- The Ultrasound Study of Tamoxifen.

Breast Neoplasms, or Breast Cancer Clinical Trial using Taxane; Taxotere; Abraxane; Ixabepilone

The Methodist Hospital System - Recruiting 18 years or older.
- Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy..
Taxane; Taxotere; Abraxane; Ixabepilone

Breast Neoplasms, BRCA 1 Gene Mutation, or BRCA 2 Gene Mutation Clinical Trial using BMN 673; Physician's-Choice

BioMarin Pharmaceutical - Recruiting 18 years or older.
- A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center Study of BMN 673 Versus Physician's Choice in Germline BRCA Mutation Subjects With Locally Advanced and/or Metastatic Breast Cancer, Who Have Received No More Than 2 Prior Chemotherapy Regimens for Metastatic Disease.
BMN 673; Physician's-Choice

Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutatio Clinical Trial using Botulinum Toxin Type A; Sodium Chloride Solution

Mayo Clinic - Recruiting 18 years or older.
- Botulinum Toxin A in Tissue Expander Breast Reconstruction: A Double-Blinded Randomized Controlled Trial.
Botulinum Toxin Type A; Sodium Chloride Solution

Neoplasms, Breast Clinical Trial using lapatinib; trastuzumab; Aromatase inhibitor

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase III Trial to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab Plus an Aromatase Inhibitor (AI) vs. Trastuzumab Plus an AI vs. Lapatinib Plus an AI as 1st- or 2nd- Line Therapy in Postmenopausal Subjects With Hormone Receptor+, HER2+ Metastatic Breast Cancer (MBC) Who Received Prior Trastuzumab and Endocrine Therapies.
lapatinib; trastuzumab; Aromatase inhibitor

Breast Neoplasms Clinical Trial using Neratinib

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase II Study of Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer.
Neratinib

Breast Neoplasms, BRCA 1 Gene Mutation, or BRCA 2 Gene Mutation Clinical Trial using BMN 673

BioMarin Pharmaceutical - Recruiting 18 years or older.
- A Phase 2, 2-Stage, 2-Cohort Study of BMN 673 in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation.
BMN 673

Breast Neoplasms Clinical Trial using Aromasin (exemestane)

Pfizer - Recruiting 18 years or older.
- A Prospective Non-Interventional Study Of China Early Invasive Breast Cancer Patients Receiving Adjuvant Therapy With Aromasinr.
Aromasin (exemestane)

Breast Neoplasms Clinical Trial using Sorafenib (Nexavar, BAY43-9006); Eribulin

Bayer - Recruiting 18 years or older.
- A Phase 1, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Sorafenib (BAY43-9006) in Combination With Eribulin in Subjects With Advanced, Metastatic or Refractory Solid Tumors.
Sorafenib (Nexavar, BAY43-9006); Eribulin

Lung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Ne Clinical Trial using Mithramycin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum.
Mithramycin

Breast Neoplasms Clinical Trial using Vinorelbine 25 mg/m2 weekly; Afatinib 40mg once daily (OD); Paclitaxel 80 mg/m2 weekly

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- LUX-Breast 2; An Open Label, Phase II Trial of Afatinib (BIBW 2992) in Patients With Metastatic HER2-overexpressing Breast Cancer Failing HER2-targeted Treatment in the Neoadjuvant and/or Adjuvant Treatment Setting.
Vinorelbine 25 mg/m2 weekly; Afatinib 40mg once daily (OD); Paclitaxel 80 mg/m2 weekly

Neoplasms Clinical Trial using bevacizumab plus docetaxel

Tampere University Hospital - Recruiting 18 years or older.
- Single Arm Study of the Combination of Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer.
bevacizumab plus docetaxel

Melanoma, Breast Neoplasms, Lobular Carcinoma, Triple-negative Br Clinical Trial using LGK974

Novartis - Recruiting 18 years or older.
- A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands.
LGK974

Neoplasms, Breast Clinical Trial using GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Placebo

GlaxoSmithKline - Recruiting 18 years or older.
- Study of GSK2302024A Antigen-Specific Cancer Immunotherapeutic Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer.
GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Placebo

Prostatic Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Mela Clinical Trial using Interactive Voice Response (IVR) Reminders

Michigan State University - Recruiting 21 years or older.
- Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR.
Interactive Voice Response (IVR) Reminders

Breast Neoplasms, or Healthy Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Characterization of High Risk Breast Duct Epithelium by Cytology, Breast Duct Endoscopy, and cDNA Gene Expression Profile.

Breast Neoplasms, or Ovarian Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer.

Hormone Receptor-Positive Breast, Gynecologic, Desmoid, or Hormon Clinical Trial using z-Endoxifen; [(18)F] Fluoroestradiol

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors.
z-Endoxifen; [(18)F] Fluoroestradiol

Breast Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Pancre Clinical Trial using ý1ýPb-TCMC-Trastuzumab; trastuzumab

Areva Med LLC - Recruiting 19 years or older.
- Phase I Trial of Intraperitoneal ý1ýPb-TCMC-Trastuzumab for HER-2 Expressing Malignancy.
ý1ýPb-TCMC-Trastuzumab; trastuzumab

Breast Neoplasms Clinical Trial using Trastuzumab; pertuzumab; lapatinib

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib.
Trastuzumab; pertuzumab; lapatinib

Breast Neoplasms Clinical Trial using Letrozole

Samuel Lunenfeld Research Institute, Mount Sinai Hospital - Recruiting N/A or older.
- Patient-related Predictors of Estrogen Suppression in Postmenopausal Women Using Adjuvant Letrozole.
Letrozole

Breast Neoplasms Clinical Trial

Medical University of Graz - Recruiting 18 years to 80 years.
- Prospective Validation of Genomic Signatures to Predict Treatment Response in the Axillary Nodes After Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer.

Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm Clinical Trial using Alisertib; Pazopanib

University of Illinois at Chicago - Recruiting 18 years or older.
- Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors.
Alisertib; Pazopanib

Breast Neoplasms Clinical Trial using Doxorubicin; Trastuzumab; Cyclophosphamide; Paclitaxel

Washington University School of Medicine - Recruiting 18 years or older.
- A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells.
Doxorubicin; Trastuzumab; Cyclophosphamide; Paclitaxel

Neoplasms, Breast Clinical Trial

GlaxoSmithKline - Recruiting 18 years or older.
- A Prospective, Exploratory Observational Study Evaluating Specific Biomarkers in Primary Invasive Breast Cancer and Their Modulation by Standard Neoadjuvant Therapy.

Breast Neoplasms, HER2 Protein, Human, or Geriatric Health Servic Clinical Trial using Lapatinib; Trastuzumab; laboratory biomarker analysis; pharmacological study

City of Hope Medical Center - Recruiting 60 years or older.
- Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer.
Lapatinib; Trastuzumab; laboratory biomarker analysis; pharmacological study

Breast Neoplasms Clinical Trial

Norwegian University of Science and Technology - Recruiting 18 years or older.
- HR MAS MR Spectroscopy of Breast Cancer Tissue.

Breast Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Clinical Trial using Botulinum Toxin-A; Saline

University of British Columbia - Recruiting 21 years or older.
- The Use of Botulinum Toxin-A in Two-stage Tissue Expander/Implant Breast Reconstruction: A Prospective, Randomized, Double-Blind Placebo Controlled Trial.
Botulinum Toxin-A; Saline

Breast Neoplasms Clinical Trial

University Medical Centre Groningen - Recruiting 18 years or older.
- Study of the Cardiovascular and Psychosocial Effects of the Treatment of Breast Cancer With Chemotherapy and/or Radiotherapy.

Breast Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Breast Cancer Subjects.

Breast Neoplasms Clinical Trial using spiritual support; relaxation therapy

University of Sao Paulo - Recruiting 18 years or older.
- Effect of the Nursing Intervention 'Spiritual Support' in the Level of Spirituality and Clinical Parameters in Women With Breast Cancer: a Randomized Clinical Trial.
spiritual support; relaxation therapy

Breast Neoplasms Clinical Trial using Gadofosveset enhanced MRL of axillary lymph nodes

Maastricht University Medical Center - Recruiting 18 years or older.
- Non-invasive Nodal Staging in Breast Cancer With Magnetic Resonance Imaging Lymphography Using Gadofosveset.
Gadofosveset enhanced MRL of axillary lymph nodes

Breast Neoplasms Clinical Trial using Permanent breast seeds implant

Sunnybrook Health Sciences Centre - Recruiting 50 years or older.
- A Multicentre Registry Study of Permanent Breast Seed Implant (PBSI) for Early Stage Breast Cancers..
Permanent breast seeds implant

Breast Neoplasms Clinical Trial using Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- Comparison of Carbon Nanotube X-ray Stationary Digital Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions..
Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner

Breast Neoplasms, Endocrine Breast Diseases, or Neoplasm Metastas Clinical Trial using letrozole; lapatinib; everolimus

University of Maryland - Recruiting 18 years or older.
- GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer.
letrozole; lapatinib; everolimus

Operable Breast Neoplasms Clinical Trial using letrozole (Femara)

Danish Breast Cancer Cooperative Group - Recruiting 60 years or older.
- Randomized Trial of Endocrine Therapy Against Locoregional Therapy First. A DBCG Trial in Postmenopausal Patients With Operable Hormone Receptor Positive Tumors Larger Than 2 cm..
letrozole (Femara)

Breast Neoplasms, or Neoplasm Metastasis Clinical Trial

Beijing Cancer Hospital - Recruiting 18 years to 75 years.
- Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy.

Breast Neoplasms, Neoplasm Metastasis, Gene Expression Profiling, Clinical Trial using cytokine

Beijing Cancer Hospital - Recruiting 18 years to 75 years.
- Gene Expression Profiling of Breast Cancer Cells in Pleural Effusion Prodict the Response of Malignant Pleural Effusion to Immunotherapy.
cytokine

Breast Neoplasms Clinical Trial using Contrast-enhanced MR mammography

UMC Utrecht - Recruiting 18 years to 75 years.
- MR Mammography: Randomized Controlled Trial to Study Efficiency of MR Mammography in Reducing the Number of Invasive Interventions in Nonpalpable Suspicious Breast Lesions. The MONET - Study.
Contrast-enhanced MR mammography

Breast Neoplasms Clinical Trial using Docetaxel; Capecitabine; Docetaxel/Capecitabine

Georgia Center for Oncology Research & Education - Recruiting 18 years or older.
- Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer.
Docetaxel; Capecitabine; Docetaxel/Capecitabine

Breast Neoplasms Clinical Trial

National Taiwan University Hospital - Recruiting 30 years or older.
- .